Skip to main content
Swing Capital

Sanofi India Ltd

NSE: SANOFI BSE: 500674Pharma

Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]

₹3,197
52W: ₹3151 — ₹6410
PE 22.4 · Book ₹326 · +881% vs book
Market Cap₹7,362 Cr
Stock P/E22.4Price to Earnings
ROCE57.5%Return on Capital
ROE43%Return on Equity
Div. Yield2.34%Face Value ₹10

Strengths

  • +Company is almost debt free.
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 47.8%
  • +Company has been maintaining a healthy dividend payout of 71.8%

Weaknesses

  • −Stock is trading at 9.76 times its book value
  • −The company has delivered a poor sales growth of -8.74% over past five years.

Shareholding Pattern

Promoters60.4%
FIIs5.65%
DIIs21.12%
Public12.84%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters60.4%60.4%60.4%60.4%60.4%60.4%60.4%60.4%
FIIs5.81%5.78%▼0.05.64%▼0.15.58%▼0.15.61%▲0.05.57%▼0.05.55%▼0.05.65%▲0.1
DIIs22.6%22.62%▲0.022.94%▲0.323.02%▲0.123.06%▲0.022.28%▼0.821.3%▼1.021.12%▼0.2
Public11.21%11.2%▼0.011.04%▼0.211.01%▼0.010.94%▼0.111.75%▲0.812.75%▲1.012.84%▲0.1

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales469511464524515536406475420472
Expenses370374348404397364311341330330
Operating Profit1001371161201181729513490143
OPM %21%27%25%23%23%32%23%28%22%30%
Net Profit1381371038291120707662103
EPS ₹59.8759.3944.9635.7439.751.9630.2233.0426.8344.61

AI Insights

Revenue Trend

TTM revenue at ₹1,774Cr, down 3.4% YoY. OPM at 26%.

Debt Position

Borrowings at ₹18Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.

Capex Cycle

CWIP at ₹12Cr (4% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 21.12% (+1.47pp change). FIIs: 5.65% (-1.07pp change). Promoters hold 60.4%.

Margin & Efficiency

ROCE improving from 22% (Dec 2014) to 58% (Dec 2025). Working capital days: 7.

Valuation

PE 22.4x with 57.5% ROCE. Price is 881% above book value of ₹326. Dividend yield: 2.34%.

Recent Announcements